Middleton Brawner Floyd

This inventor holds 21 USPTO granted patents, plus 2 CIPO patents, primarily in Pharmaceutical Chemistry. Top assignees: American Cyanamid Company, Wyeth Holdings Corporation, Wyeth. Active years: 1976-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Middleton Brawner Floyd. Retrieved from https://idiyas.com/inventor/middleton-brawner-floyd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21

% Patents Active = 85.7

CIPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 2.9

ph-index = 9

Forward Citations = 193(Granted Patents)

Company Filing History:

18 out of 3,580

American Cyanamid Company

patents

2 out of 113

Wyeth Holdings Corporation

Years Active: 1976-2010

Loading Chart...

Areas of Expertise:

3-Cyanoquinolines

EGF-R Inhibitors

HER2 Kinases

Prostanoic Acids

Alkoxyquinolones

Dihydro-Prostaglandins

Furan Derivatives

Synthesis Processes

Amide Derivatives

Alkynes

Epoxycyclopentanones

Lithium Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7713994 - [object Object] (2010-05-11),

2. 6933388 - Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolones (2005-08-23),

3. 6821988 - 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases (2004-11-23),

4. 4110368 - Hydro substituted prostanoic acids and esters (1978-08-29),

5. 4107441 - Novel 16 hydroxy 15-deoxy-5-cis-prostenoic acids and esters (1978-08-15),

6. 4076732 - Derivatives of .alpha.-(6-carboxyhexyl) furfuryl alcohol (1978-02-28),

7. 4061672 - Derivatives of 9-hydroxy-13-trans-prostenoic acid (1977-12-06),

8. 4061670 - 15-Deoxy-16-hydroxy-16-vinyl and cyclopropyl substituted prostanoic (1977-12-06),

9. 4060540 - Novel 3-triphenylmethoxy-1-alkynes, (1977-11-29),

10. 4054604 - Amide derivatives of 9-oxo-13-trans-prostenoic acid (1977-10-18),

11. 4044043 - Derivatives of 9-oxo-13-trans-prostenoic acid esters (1977-08-23),

12. 4021452 - 2,5-Dihydro-2,5-dialkoxyfuran derivatives (1977-05-03),

13. 4017534 - 16-Fluoro-11-deoxy-13-dihydro-prostaglandin (1977-04-12),

14. 4007210 - Novel 3-triphenylmethoxy-1-alkynes, (1977-02-08),

15. 3985798 - 11.alpha.-HOMO-PROSTANOIC ACIDS AND ESTERS (1976-10-12),

Title: The Inventive Journey of Middleton Brawner Floyd

Introduction:

Middleton Brawner Floyd, a prolific inventor hailing from Suffern, NY (US), has made significant contributions to the field of pharmaceuticals with an impressive 21 patents to his name. His relentless pursuit of innovation has led to groundbreaking advancements in the synthesis of key compounds used in the treatment of cancer.

Latest Patents:

Among his latest patents is a revolutionary invention involving compounds of Formula (I), which play a crucial role in the development of protein tyrosine kinase (PTK) inhibitors for cancer treatment. Additionally, Floyd's patent on the process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolones showcases his expertise in designing efficient methods for the preparation of vital pharmaceutical intermediates.

Career Highlights:

Middleton Brawner Floyd has left an indelible mark on esteemed companies such as American Cyanamid Company and Wyeth Holdings Corporation. His tenure at these organizations has been marked by a relentless pursuit of innovation and a commitment to pushing the boundaries of pharmaceutical research and development.

Collaborations:

Throughout his career, Floyd has collaborated with esteemed colleagues such as Martin J Weiss and Robert E Schaub. These collaborations have been instrumental in driving forward his inventive work and achieving groundbreaking results in the field of pharmaceutical chemistry.

Conclusion:

Middleton Brawner Floyd stands as a testament to the power of relentless innovation and dedication to scientific advancement. His pioneering work in pharmaceutical research has not only earned him recognition but has also significantly contributed to the development of crucial treatments for cancer. As he continues to push the boundaries of scientific discovery, Floyd's legacy as a visionary inventor remains unmatched.

Profile summary based on public USPTO records.